Paricalcitol Attenuates Renal Interstitial Fibrosis in Obstructive Nephropathy
Open Access
- 1 December 2006
- journal article
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 17 (12) , 3382-3393
- https://doi.org/10.1681/asn.2006050520
Abstract
Deficiency in vitamin D and its active metabolites is a pathologic feature of chronic kidney diseases. Despite that tubular epithelial cells are the major sites of active vitamin D synthesis, little is known about the role of vitamin D in maintaining the structural and functional integrity of tubular epithelium. This study investigated the effects of paricalcitol (19-nor-1,25-hydroxy-vitamin D2), a synthetic vitamin D analogue, on obstructive nephropathy, a model that is characterized by predominant tubulointerstitial lesions. Compared with vehicle controls, paricalcitol significantly attenuated renal interstitial fibrosis in mouse kidney after ureteral obstruction, as demonstrated by a reduced interstitial volume, decreased collagen deposition, and repressed mRNA expression of fibronectin and type I and type III collagens. Paricalcitol largely preserved E-cadherin and reduced α-smooth muscle actin expression in vivo. In addition, paricalcitol suppressed renal TGF-β1 and its type I receptor expression, restored vitamin D receptor abundance, and inhibited cell proliferation and apoptosis after obstructive injury. In vitro, paricalcitol abolished TGF-β1–mediated E-cadherin suppression and α-smooth muscle actin and fibronectin induction in tubular epithelial cells, underscoring its ability to block directly the epithelial to mesenchymal transition (EMT). It is interesting that paricalcitol almost completely suppressed renal induction of Snail, a critical transcription factor that is implicated in EMT programming. Furthermore, paricalcitol inhibited the TGF-β1–mediated Snail induction in vitro, and ectopic expression of Snail repressed E-cadherin promoter activity and downregulated E-cadherin expression in tubular epithelial cells. These studies suggest that paricalcitol is able to ameliorate renal interstitial fibrosis in obstructive nephropathy, possibly by preserving tubular epithelial integrity through suppression of EMT.Keywords
This publication has 42 references indexed in Scilit:
- Renal fibrosis: New insights into the pathogenesis and therapeuticsKidney International, 2006
- Antiproteinuric effect of oral paricalcitol in chronic kidney diseaseKidney International, 2005
- VITAMIN D IN HEALTH AND DISEASE: Vitamin D for Health and in Chronic Kidney DiseaseSeminars in Dialysis, 2005
- Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidismKidney International, 2003
- Update on vitamin D and its newer analogues: Actions and rationale for treatment in chronic renal failureKidney International, 2002
- Vitamin D3 promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of β-catenin signalingThe Journal of cell biology, 2001
- A Vitamin D Analog Ameliorates Glomerular Injury on Rat GlomerulonephritisThe American Journal of Pathology, 2001
- The transcription factor Snail controls epithelial–mesenchymal transitions by repressing E-cadherin expressionNature Cell Biology, 2000
- The transcription factor Snail is a repressor of E-cadherin gene expression in epithelial tumour cellsNature Cell Biology, 2000
- A simple micromethod for collagen and total protein determination in formalin-fixed paraffin-embedded sections.Journal of Histochemistry & Cytochemistry, 1985